Anemia & Fatigue

Nutrients Depleted by Bydureon

Some side effects may be linked to nutrient depletion caused by this medication.

• Folic Acid — Depletion

  GLP 1 receptor agonists, used for both diabetes and weight management, can indirectly increase the risk of folate deficiency because they reduce overall food intake in a population that already tends to have low folate intake. Studies with potent incretin agonists show that when these drugs markedly suppress appetite and drive weight loss, blood folate levels can drop and then improve again when intake is restored, supporting a link between reduced intake and folate deficiency. In practice, this has prompted experts to emphasize monitoring folate status and diet quality in GLP 1 users, and many now recommend ensuring folate needs are met, often with folate or B complex supplement, for patients with low intake or anemia risk.

• Zinc — Depletion

  GLP‑1 receptor agonists, used for diabetes and weight management, can increase the risk of zinc deficiency because they significantly reduce overall food intake in people who often start out with marginal zinc status. Observational data in GLP‑1 users show rising diagnoses of mineral deficiencies, including zinc, over the first year of therapy, consistent with lower intake and rapid weight loss. To help maintain immune function, wound healing, and normal taste and smell, many experts recommend emphasizing zinc‑rich foods and supplementation for patients with low intake, hair loss, or other deficiency signs.

• Vitamin B12 — Depletion

  GLP‑1 receptor agonists, medications used for diabetes and weight management, can interfere with the absorption of vitamin B12, especially when they are used long term. Vitamin B12 is essential for healthy nerve function, red blood cell production, and normal hair growth, so deficiency may show up as fatigue, low mood, nerve issues, anemia, or increased hair shedding. Because of this, many clinicians recommend vitamin B12 supplementation alongside GLP‑1 therapy to help maintain overall health.

• Iron — Depletion

  GLP-1 RA therapy can be associated with lower iron stores in some patients by reducing intake and absorption, but not all users need or should take extra iron. Because some people have high ferritin or genetic HFE variants, routine iron use may be harmful rather than helpful. Users should have periodic blood tests to have iron levels and CBC checked, and only use iron if iron-deficiency anemia is confirmed and clinically indicated.

• Calcium — Depletion

  Early data suggest small but measurable impacts of GLP 1 therapy on bone health and fracture risk in some users. In a large cohort of older adults with type 2 diabetes, new GLP 1 receptor agonist users had an 11% higher risk of fragility fractures over roughly three years compared with users of other diabetes drugs, supporting concern about skeletal vulnerability during treatment. Taken together with trials showing modest losses in hip and spine bone mineral density during GLP 1–associated weight loss, these findings are prompting clinicians to pay closer attention to calcium and vitamin D intake, resistance exercise, and fall and fracture prevention strategies in GLP 1 users.

• Vitamin D3 — Depletion

  GLP‑1 receptor agonists, used for diabetes and weight management, can raise the risk of vitamin D deficiency because they substantially reduce overall food intake in people who are often starting from a low baseline. Emerging data in GLP‑1 users show high rates of low vitamin D and other nutritional deficiencies, which may compound age and obesity related risks for bone loss and loss of muscle mass. To help support bone health, muscle maintenance, and immune function during rapid weight loss, many experts recommend ensuring adequate vitamin D through diet, sensible sun exposure, and vitamin D supplementation.

• Magnesium — Suppression

  Magnesium insufficiency is a concern for people taking GLP‑1 receptor agonists because reduced appetite and smaller portions often lower overall magnesium intake, which is already borderline for many adults. This matters because magnesium is essential for muscle and nerve function, glucose metabolism, bone health, sleep quality, and bowel regularity, and GLP‑1–related nausea, vomiting, or diarrhea can further impair intake and absorption. In this context, many clinicians suggest emphasizing magnesium‑rich foods and supplementation.

• Potassium — Suppression

  Potassium plays a key role in supporting heart rhythm and muscle function for GLP‑1 RA users, helping counter losses from nausea, vomiting, or diarrhea that affect up to about 1 in 5 patients on these drugs. Maintaining normal serum potassium in the 3.5–5.0 mEq/L range is critical because levels below 3.0 mEq/L can trigger dangerous arrhythmias and severe muscle weakness, especially when GLP‑1 side effects and diuretics are combined. Emerging clinical reports also highlight that GLP‑1 users may have a significant shortfall of dietary potassium making proactive intake from potassium‑rich foods and supplementation critical.

• Vitamin B6 — Suppression

  GLP-1 receptor agonists can substantially reduce overall food and micronutrient intake as appetite and meal size decline. In a prospective study of adults starting semaglutide or tirzepatide, vitamin B6 intake declined significantly over 24 weeks, supporting the importance of maintaining adequate B6 during therapy. However, other GLP-1 studies have not demonstrated a consistent B6 deficiency signal, so its role is best viewed as nutritional coverage during reduced intake rather than replacement of a nutrient directly depleted by GLP-1s. B6 is essential for amino acid metabolism, neurotransmitter synthesis, and cellular energy pathways.

• CoQ10 — Suppression

  CoQ10 plays a critical role in supporting cellular energy and metabolic health in a population with a high prevalence of insulin resistance and type 2 diabetes. CoQ10 is an essential component of mitochondrial energy production and antioxidant defense. Large meta-analyses of randomized trials have found modest improvements in several measures of glucose metabolism with supplementation, particularly in people with diabetes, although results and evidence certainty remain mixed. Its role in the formula is therefore metabolic and cellular-energy support rather than correction of a GLP-1-specific nutrient deficiency.

• Vitamin B2 — Suppression

  Riboflavin is important for cellular energy production and serves as a cofactor in pathways that activate and utilize other B vitamins. While reduced food intake during GLP-1 therapy creates a broader rationale for maintaining B-vitamin coverage, current studies do not identify riboflavin as a common GLP-1-related deficiency. In fact, available dietary studies generally show adequate riboflavin intake among GLP-1 users. Its inclusion is therefore best positioned as foundational support for energy and nutrient metabolism during reduced-calorie intake, rather than correction of a demonstrated GLP-1 nutrient deficiency.

• Chromium — Suppression

  Chromium has an adjacent metabolic rationale with GLP-1 use because of its relationship with insulin action and glucose metabolism. Meta-analyses of randomized trials in people with type 2 diabetes have reported improvements in fasting glucose, insulin, HbA1c, and insulin-resistance measures with chromium supplementation, although results vary substantially across studies. Importantly, evidence does not consistently support chromium for weight or fat loss, so it should not be positioned as a weight-loss enhancer. Chromium picolinate is one of the most extensively studied supplemental forms for metabolic support.